Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abarelix

FDA-approved product (powder, intramuscular), marketed as Plenaxis.

Registered studies
5
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Abarelix
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other hormone antagonists and related agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

5registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abarelix in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abarelix with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

    NCT06379217 · start 2024-07-29

    Registered record
    Registry ID
    NCT06379217
    Conditions
    Metastatic Neuroendocrine Prostate Cancer
    Interventions
    [68Ga]Ga-PSMA-11; [68Ga]GA-DOTA-TATE; [68Ga]Ga-NeoB; [177Lu]Lu-PSMA-617; [177Lu]Lu-DOTA-TATE; [177Lu]Lu-NeoB; L-Lysine HCl-L-Arginine HCl, 2.5 %,; Gonadotropin-releasing hormone (GnRH) analogues; GnRH antagonists; Antiemetics & antinauseants; Metoclopramide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2024-07-29
    Completion
    2026-08-31
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Neuroendocrine Prostate Cancer
    Intervention[68Ga]Ga-PSMA-11; [68Ga]GA-DOTA-TATE; [68Ga]Ga-NeoB; [177Lu]Lu-PSMA-617 +7 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Diagnosis of Pelvic Endometriosis in MRI

    NCT06157528 · start 2023-12-20

    Registered record
    Registry ID
    NCT06157528
    Conditions
    Endometriosis
    Interventions
    Magnetic resonance imaging
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2023-12-20
    Completion
    2029-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionMagnetic resonance imaging
    PhaseNot applicable
    Registry statusNot yet recruiting

  • The Plenaxis® Experience Study

    NCT00103623 · start 2004-06

    Registered record
    Registry ID
    NCT00103623
    Conditions
    Prostate Cancer
    Interventions
    Plenaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Suspended
    Start
    2004-06
    Completion
    2008-12
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPlenaxis
    PhasePhase 4
    Registry statusSuspended

  • Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

    NCT00100243 · start 2004-05

    Registered record
    Registry ID
    NCT00100243
    Conditions
    Prostate Cancer
    Interventions
    Plenaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-05
    Completion
    2005-09
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPlenaxis
    PhasePhase 2
    Registry statusCompleted

  • Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer

    NCT00841113 · start 1999-01

    Registered record
    Registry ID
    NCT00841113
    Conditions
    Prostate Cancer
    Interventions
    Abarelix; Goserelin plus Bicalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-01
    Completion
    2003-02
    Enrolment
    177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAbarelix; Goserelin plus Bicalutamide
    PhasePhase 3
    Registry statusCompleted